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ABSTRACT
There is a compelling need for new therapeutic strategies for glioblastoma 
multiforme (GBM). Preclinical target and therapeutic discovery for GBMs is primarily 
conducted using cell lines grown in serum-containing media, such as U-87 MG, which 
do not reflect the gene expression profiles of tumors found in GBM patients. To 
address this lack of representative models, we sought to develop a panel of patient-
derived GBM models and characterize their genomic features, using RNA sequencing 
(RNA-seq) and growth characteristics, both when grown as neurospheres in culture, 
and grown orthotopically as xenografts in mice. When we compared these with 
commonly used GBM cell lines in the Cancer Cell Line Encyclopedia (CCLE), we found 
these patient-derived models to have greater diversity in gene expression and to 
better correspond to GBMs directly sequenced from patient tumor samples. We also 
evaluated the potential of these models for targeted therapy, by using the genomic 
characterization to identify small molecules that inhibit the growth of distinct subsets 
of GBMs, paving the way for precision medicines for GBM.
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INTRODUCTION
Glioblastoma multiforme is the most common 
form of primary brain cancer in adults and is a deadly 
disease associated with extremely poor prognoses [1]. 
After diagnosis, patients have a median survival of 15 
months with current standard-of-care therapies of surgery 
followed by chemotherapy and radiation [2]. Therefore, 
new therapeutic strategies, specifically targeted therapy, 
need to be explored for this disease. To that end, previous 
studies explored in vitro compound sensitivities in 
glioblastoma using cell lines cultured in the presence 
of serum, such as those from the Cancer Cell Line 
Encyclopedia (CCLE [3]. However, it has been shown 
that GBM cancer cell lines cultured with serum poorly 
represent the gene expression profile and physiology 
of GBM tumors in patients, and exhibit considerable 
divergence from the original tumors from which they 
were derived [4]. We have previously demonstrated that 
glioblastoma-patient-derived neurosphere cultures (serum-
free) are able to preserve the parental tumor somatic 
mutations and copy number alterations, including extra-
chromosomal oncogene amplification [5]. We have also 
demonstrated that these patient-derived neurospheres can 
be used to conduct high-throughput screens using small-
molecules [6]. Here, we sought to extend the usefulness 
of these models by analyzing the gene expression profiles 
and mutation status of these patient-derived models 
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using RNA sequencing. We have found through RNA 
sequencing of GBM neurospheres that we can predict 
sensitivity to small molecule inhibitors in some cases, 
paving the way for novel targeted therapies in GBM.
RESULTS
Isolation and in vitro growth of patient-derived 
glioblastoma samples
Patient-derived glioma samples were collected 
at Henry Ford Hospital as previously described 
[7]. Dissociated cells from 22 glioblastomas and 1 
oligodendroglioma were propagated, both in vitro and 
in vivo, to evaluate which would be amenable to in vitro 
high-throughput screening with small molecules (Figure 
1A). If cells could not be consistently propagated as 
neurospheres in culture, laminin was added to the culture 
flask to a concentration of 1 µg/cm2, to allow cells to 
grow in 2D. We determined the optimal in vitro culture 
conditions as well as average doubling time, of each 
patient-derived model (Table 1). Of these, fifteen grew 
successfully as neurospheres in conditions suitable for 
high-throughput screening, three grew with the addition 
of laminin, and five were unable to survive long-term in 
culture under either condition. The doubling time of the 
cultures ranged widely between 84 hours (HF3026) and 
625 hours for the oligodendroglioma model (HF3309).
In vivo growth characteristics of orthotopic 
xenograft tumor models
We then orthotopically implanted 15 of the GBM 
models into immunocompromised mice to evaluate which 
were able to form tumors in vivo and were suitable for 
further experimentation. We found that eight models 
were able to form at least one tumor visible by MRI 
when orthotopically xenografted into mice, within 28 
days (HF3177) to 159 days (HF2876) post implant 
(Table 2). Following the injection of gadolinium contrast, 
we observed that tumors formed by 4 of the cell lines 
(HF2303, HF2609, HF3013, HF3177) appeared “leaky” 
on the images, indicating compromise of the blood-brain 
barrier within the tumors, a hallmark of GBMs [8]. The 
growth curves for three of the fastest-growing tumor 
models (HF2303, HF3013, HF3177) are shown in Figure 
2A, and representative MRI images of these tumors are 
shown in Figure 2B.
RNA-seq and mutational analysis highlights 
diversity of patient-derived glioblastoma samples 
compared to those from the CCLE
Next, we used RNA sequencing to analyze gene 
expression in each of the 23 patient-derived glioma 
models. In addition, tumors from four orthotopic xenograft 
models in mice (HF2303, HF2609, HF3013, HF3177) 
were sequenced, and three patient glioblastoma tissue 
samples taken directly from patients (HF2876, HF3177, 
and HF3216) were also sequenced. Additionally, raw 
RNAseq FASTQ files from 28 GBM cell lines from the 
CCLE were reprocessed using the same pipeline.
We observed that the patient-derived models, as a 
whole, represented a more heterogeneous gene expression 
profile compared to the CCLE models, which better reflect 
the disease’s diversity. Analyzing genes relevant to GBM, 
we found high levels of MET mRNA expression in 21/28 
CCLE lines, and in 2/23 patient-derived models (Figure 
3A). MET gene is amplified in about 4% of GBMs, and 
mRNA overexpression is observed in about 11% [9]. 
This demonstrates that GBM cell lines grown in culture 
containing serum tend to become more mesenchymal 
Figure 1: Isolation and growth characterization of new GBM models. (A) Illustration of the process of isolation, propagation, 
and analysis of patient-derived glioblastoma models.
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while deviating from pro-neural tumors transcriptionally 
similar to oligodendrocyte progenitor cells, while also 
losing their stem cell-like qualities. This is consistent with 
the finding that pro-neural glioma stem-like cells found 
in GBMs, when cultured under conditions containing 
serum, showed an induction of mesenchymal gene 
expression signatures [10]. This effect was not observed 
in the spheroid model cultures, suggesting that serum-
free culture of spheroid models can better preserve the 
genomic characteristics of GBMs in patients. Next, we 
examined the mutation status of several genes relevant 
to GBM and ferroptosis, because several ferroptosis-
inducing compounds were included in the small molecule 
sensitivity screen (Figure 3B). Neurosphere cultured 
models were more likely to be NF1 mutant, and less likely 
to be TP53 mutant, compared to CCLE. We were also able 
to culture one model with an EGFR fusion and one with a 
gain of function MET mutation, neither of which exists in 
the CCLE GBM cohort. For genes related to ferroptosis, 
only three neurospheres expressed significantly high or 
low levels of GPX4, SLC7A11, or ACSL4, compared to one 
in the CCLE cohort. Finally, principle component analyses 
(PCA) showed that patient-derived neurosphere cultures, 
and even more so mouse xenografts, are transcriptionally 
more similar to patient samples than GBM cell lines in the 
CCLE (Figure 3C).
MDM2 copy number, p53 mutation status, and 
EGFR mutation status predict cell line sensitivity 
to small-molecule inhibitors
In our small-molecule screen using patient-derived 
GBM neurospheres, one of the most striking features 
was the potency and patient-model-selectivity of the 
MDM2-p53 interaction inhibitor class of compounds. 
For example, nutlin-3A yielded a >500-fold change in 
EC50 between the most sensitive (HF2381, EC50 = 212 
nM) and most resistant (HF3013, EC50 > 100 µM) lines 
(Figure 4A and Table 3). When we compared the sensitivity 
profile across 12 neurosphere models with their respective 
RNA-seq data, we found a strong correlation between the 
MDM2 overexpression and p53 mutation status inherent 
Table 1: Overview of GBM growth characteristics in vitro
Cell line Optimal growth condition for HTS Average doubling time in vitro (h)
HF2303 Neurospheres 179
HF2381 Neurospheres 153
HF2414 None N/A
HF2476 Laminin 122
HF2485 None N/A
HF2561 None N/A
HF2562 Neurospheres 165
HF2575 Neurospheres 87
HF2609 None N/A
HF2790 Neurospheres 143
HF2876 Laminin 97
HF2885 Laminin 173
HF2906 Neurospheres 226
HF2941 Neurospheres 85
HF2998 Neurospheres 87
HF3013 Neurospheres 91
HF3019 Neurospheres 77
HF3026 Neurospheres 84
HF3037 Neurospheres 117
HF3177 Neurospheres 185
HF3216 None N/A
HF3309 Neurospheres 625
HF3373 Neurospheres 134
Optimal growth conditions and average doubling time of patient-derived GBM cultures were recorded (n = 23).
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to each cell line, and their sensitivity to the small-molecule 
inhibitors YH239-EE, RG7112, nutlin-3A, which disrupt 
binding of p53 to MDM2, as well as pifithrin-µ, which 
targets mitochondrial p53. Using hierarchical clustering, 
we observed that the models most sensitive to these 
compounds were those with highest MDM2 expression, as 
well as those with wild-type p53 (Figure 4B). On the other 
hand, the least sensitive cells were those with lower MDM2 
predicted copy number and those with p53 mutations. From 
the combination of sensitivity data for small molecules 
and RNA-seq data, we may be able to better predict GBM 
patients that can benefit from targeted therapeutics.
Furthermore, we noted that a specific EGFR 
fusion conferred sensitivity to the small molecule EGFR 
Table 2: Growth characteristics of GBM cell lines after orthotopic xenograft in mice
Cell line Number of mice with tumor Number of days to first tumor formation
Contrast agent leakage 
seen on MRI
HF2303 5/5 47 yes
HF2381 0/4 N/A N/A
HF2414 0/4 N/A N/A
HF2476 0/5 N/A N/A
HF2561 4/4 144 no
HF2609 2/4 80 yes
HF2790 3/5 40 no
HF2876 4/4 159 no
HF2885 0/3 N/A N/A
HF2906 0/3 N/A N/A
HF2998 1/4 42 no
HF3013 4/5 36 yes
HF3026 0/4 N/A N/A
HF3037 0/5 N/A N/A
HF3177 4/5 28 yes
For each cell line (n = 15), the tumor take rate in mice, the number of days to first tumor formation, and whether contrast 
agent leakage was observed on MRI were recorded.
Figure 2: In vivo characteristics of orthotopic xenograft GBM models. (A) In vivo growth curves of orthotopic xenograft 
tumors grown in mice from patient-derived neurospheres HF2303, HF3013, and HF3177, with n = 5. (B) Representative MRI images, with 
and without gadolinium contrast, of orthotopic xenograft tumors grown in mice from cell lines HF2303, HF3013, and HF3177.
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Figure 3: Comparison of gene expression and mutational status of patient-derived glioblastoma samples compared 
to those from CCLE. (A) Heatmap containing fold changes compared to the mean value of the expression of key genes of interest in 
patient-derived neurospheres vs. CCLE cell lines. Red signifies upregulation and blue signifies downregulation. (B) Mutational analysis 
of genes of interest in patient-derived neurospheres vs. CCLE cell lines. Dark green: loss-of-function SNV or indel. Lime: known gain-
of-function SNV. Green: likely loss-of-function SNV (present in COSMIC). Mustard: SNV of unknown function. Purple triangle: EGFR 
fusion. Red: High expression (> 500 TPM or > 2IQR over median). Blue: Low expression (< 1 TPM or < 2IQR below median). (C) 
Principal component analyses of RNA sequencing data between GBM neurospheres sequenced as spheroid cultures (green), as orthotopic 
xenografts (orange), or as patient samples (red) and cell lines obtained from CCLE (blue).
Figure 4: Discovery of MDM2 inhibitor sensitivity correlation with MDM2 copy number and p53 mutational status. 
(A) Dose response of the 3 most sensitive and 3 most resistant GBM neurosphere models to Nutlin-3A, RG7112, and YH239-EE. Among 
the more sensitive cell lines with wild-type p53 (black), HF2885 and HF2381 are also predicted to be MDM2-amplified by RNA sequencing. 
Data are plotted as mean ± SD, with n = 3 side-by-side experimental replicates. (B) Heatmap showing correlation between MDM2 copy 
number and p53 mutation status and MDM2 inhibitor differential sensitivity across GBM lines. Color values are a Z score of log10 (EC50) 
for each compound in each line. Darker colors represent more sensitive cell lines to the compound. (C) Dose response of two GBMs with 
EGFR alterations to the EGFR inhibitor afatinib. HF2876 (blue) has EGFRvIII (EC50=1.324 µM), whereas HF3177 (black) has KIF5A: 
EGFR and ASAP1: EGFR fusions (EC50=0.0006 µM). GBM models with wild-type EGFR (HF2885, HF2381, HF2476, HF2941, HF3026, 
HF2998, HF2790, HF2906, HF2303, and HF3013) had EC50 above 0.96 µM, as indicated in Table 4. Data are plotted as mean ± SD, with 
n = 3 side-by-side experimental replicates.
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inhibitor afatinib (Figure 4C). In our models, although 
two GBMs were found to have with EGFR alterations, 
namely HF2876 (EGFRvIII) and HF3177 (KIF5A: EGFR 
and ASAP1: EGFR fusions), we found a large difference 
in sensitivity between the two, with the latter about 2000 
times more sensitive than the former (EC50=0.0006 µM 
for HF3117 vs. 1.324 µM for HF2876). GBMs that did not 
harbor an EGFR alteration were also relatively insensitive 
to afatinib treatment, with EC50 values ranging between 
0.96 and 3.63 µM (Table 4). In summary, a specific 
EGFR fusion provides another example of correlating 
RNA sequencing data with small molecule compound 
sensitivity.
DISCUSSION
Here, we describe the isolation and characterization 
of a panel of 22 patient-derived GBM models, which 
together represent a valuable tool for study of this disease. 
These cells can be grown in vitro either as neurospheres 
or in 2D culture on laminin or low serum, but these 
different culture conditions do not affect model sensitivity 
to a panel of small-molecule inhibitors of cell viability 
[6]. Here, we evaluated the capacity of these models to 
grow orthotopically in mice and demonstrated that at 
least 8 models were implanted with relatively high rate of 
tumor formation. As such, we suggest that these represent 
Table 3: Sensitivity of GBM models to p53-MDM2 inhibitors (EC50 in µM)
Compounds Pifithrin-μ RG7112 YH239-EE Nutlin 3A MDM2 predicted copy number
p53 mutation 
status
HF2885 0.8531 0.04785 2.234 0.189 7.76 wt
HF2381 0.857 0.009132 1.038 0.2116 55.63 wt
HF2476 1.466 0.01356 0.4542 0.313 normal wt
HF2941 1.361 0.04077 1.12 0.5516 normal wt
HF3026 0.6887 0.1334 2.153 1.284 normal wt
HF2998 0.8735 0.2632 2.8 1.809 normal wt
HF2790 1.225 0.9405 3.879 6.943 normal C242F
HF3177 1.024 0.8706 3.961 6.968 normal M133T
HF2906 0.7136 0.6126 4.61 7.93 normal R175H
HF2876 3.784 0.0818 1.959 10.73 normal wt
HF2303 3.353 0.9435 3.881 17.02 normal G245S
HF3013 3.343 1.007 6.758 100 normal V272M
The sensitivity of 12 different patient-derived GBMs in 3D neurosphere culture was determined by dose-response testing 
with each compound in triplicate. Mean EC50 values in micromolar are indicated in Table 3.
Table 4: Sensitivity of GBM models to afatinib (EC50 in µM)
Afatinib sensitivity
HF2885 0.9631
HF2381 1.024
HF2476 2.207
HF2941 1.781
HF3026 1.505
HF2998 1.589
HF2790 1.004
HF3177 0.0006084
HF2906 1.592
HF2876 1.324
HF2303 2.305
HF3013 3.633
The sensitivity of 12 different patient-derived GBMs was determined by dose-response testing with each compound in 
triplicate. Mean EC50 values in micromolar are indicated in Table 4.
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valuable model for the screening and discovery of new 
small-molecule drugs for GBM.
We analyzed the transcriptomes of the models using 
RNA sequencing. Comparison of their gene expression 
with cell lines from the CCLE revealed a greater diversity 
of expressed genes in these new models and more 
similar to those found in TCGA clinical GBM studies. 
In particular, while the classic cell culture models tend 
to universally overexpress certain stem cell markers and 
markers of EMT, this widespread pattern was not found in 
the patient-derived neurospheres. Therefore, the patient-
derived models appear to be a better representation of the 
genetic heterogeneity of the disease in patients. Indeed, 
principal component analysis of the cultures grown 
under different conditions show that the patient-derived 
models, when grown as neurospheres or as xenografts, 
have expression profiles closer to those found in patient 
samples than CCLE samples.
Using small molecule inhibitors of the p53-MDM2 
interaction, we found that the differential sensitivity of 
the panel of GBM models to small molecules could be 
correlated with MDM2 gene expression as well as TP53 
mutational status. In this case, samples with higher 
expression of MDM2 were more sensitive to MDM2 
inhibitors. Similarly, the MDM2 inhibitors were more 
potent in models with wild-type p53, as degradation 
of mutant p53 is less dependent on its interaction with 
MDM2 [11]. To further test the idea that compound 
sensitivity can be predicted by gene expression, we 
tested the EGFR inhibitor afatinib in the models, which 
were all wild-type for EGFR with the exception of two 
GBMs, which harbored EGFR amplification and either 
the constitutively active EGFRvIII variant (HF2876), or 
KIF5A: EGFR and ASAP1: EGFR fusions (HF3177). 
We found that afatinib selectively killed the GBM cell 
line with EGFR fusions, with a potency almost 2000-
fold higher than those observed in the other GBMs 
(Table 4). Taken together, we expect that the availability 
of these patient-derived GBM models with a high 
degree of genetic and transcriptional diversity will 
enable a better preclinical basis to find potential novel 
targeted therapies for glioblastoma. These models are 
readily available from the Hermelin Brain Tumor Center 
live biobank at Henry Ford Hospital. De-identified 
information about tumor type, location, treatment 
status and other patient information are recorded in 
Supplementary Tables 1 and 2.
MATERIALS AND METHODS
Contact for reagent and resource sharing
Further information and requests for resources 
and reagents should be directed to and will be fulfilled 
by the Lead Contact Brent R. Stockwell (bstockwell@
columbia. edu). The GBM models are available from 
the Hermelin Brain Tumor Center live biobank at Henry 
Ford Hospital through a Material Transfer Agreement 
(adecarv1@hfhs.org).
Cell culture
Isolation, propagation and characterization of GBM 
neurospheres were performed as previously described [7].
In vivo orthotopic xenograft
Female 8–12 weeks old athymic nude mice from 
Charles River Lab (Crl: NU (NCr)-Foxn1nu, Massachusetts 
USA) were used as hosts for xenograft implantation. 
Mice were anesthetized by isoflurane inhalation, received 
an injection of Loxicom analgesics (5 mg/kg SC) pre-
operation, and positioned in a stereotaxic frame for 
implantation (Stoelting model 51730, Illinois USA). Skin 
over the skull was scrubbed with betadine and 70% ethanol 
to maintain aseptic conditions. A midline skin incision 
and a small hole was drilled in the skull over the injection 
site. GBM cells were resuspended in sterile PBS, and 
300,000 cells in 5 ul was slowly injected into the cortex 
(3.0 mm ML, -1.0 mm AP, 1.5 mm DV from bregma) using 
a mounted Hamilton syringe. Skin incision was closed 
with nylon suture, and animals allowed to recover with 
ad libitum access to food and water. Mice were monitored 
weekly for clinical assessment scoring and body weight. 
Monitoring of tumor growth by MRI started 3–4 weeks post 
implant and was performed weekly. Mice were sacrificed 
before tumor burden associated symptoms developed.
MRI imaging and data analysis
Magnetic resonance imaging (MRI) was performed 
on a Bruker Biospec 7.0T/30 cm NMR system (Bruker 
Biospin Corp, Billerica, MA) equipped with BGA12 
gradients using a mouse brain cryoprobe. Paravision 5.1 
software was employed for data acquisition. Imaging setup 
was head first, prone position.
For MRI measurement, each mouse underwent 
gas anesthesia with 1–1.5% isoflurane in an oxygen fed 
nose cone. Paralube eye ointment was applied to the eyes 
to avoid drying during the scan. A bellows was placed 
under the body to measure respiration and a temperature 
probe was inserted rectally. Temperature was maintained 
at 35.5–36.5C using a warm water bed. Respiration and 
temperature were monitored using PC-Sam software from 
SA Instrument, New York. An 80 cm microrhenethane 
catheter with a 28G needle for insertion into the lateral 
tail vein and a 1cc syringe loaded with a gadolinium-based 
contrast agent (Magnevist, Bayer, USA) at the other end 
was placed prior to start of the imaging session.
T2-Weighted RARE 2D sequence with consecutive 
axial slices was used for volumetric imaging and 
tumor evaluation. Slices=26, Slice thickness=0.5 mm, 
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TR=3500ms, TEeff=52ms, NEX=4, MTX=256 × 256, 
Total acquisition time=7.5 mins.
Regional contrast agent uptake was assessed with 
a T1 weighted MSME sequence obtained before and 
repeated for 10 mins after a 50 uL lateral tail vein injection 
of a gadolinium-based contrast agent. The MSME was 
obtained with the same slice position and FOV as the 
previous T2 scan is obtained using parameters Slices=26, 
Slice thickness=0.5mm, TR=500ms, TE=10.1ms, NEX=1, 
MTX=128 × 128, ave=2, Total acquisition time=2.1 mins.
Paravision 5.1 software was employed for data 
processing and regions of interest were drawn manually 
for quantification of tumor volume. Blood brain barrier 
integrity was assessed by comparison of signal intensity 
in the tumor region of the brain between pre and post 
contrast MSME images.
All procedures were conducted in accordance 
with a protocol approved by the Novartis Institutes of 
BioMedical Research Inc. Institutional Animal Care and 
Use Committee (IACUC).
RNA sequencing and data analysis
Total RNA was extracted from cells using the Qiagen 
AllPrep DNA/RNA Isolation Kit (catalog number 80204). 
Total RNA was then quantified using the Agilent RNA 
6000 Nano Kit (catalog number 5067-1511) on the Agilent 
2100 BioAnalyzer. Two hundred nanograms of high purity 
RNA (RNA Integrity Number 7.0 or greater) was used as 
input to the Illumina TruSeq Stranded mRNA Library Prep 
Kit, High Throughput (catalog number RS-122-2103), and 
the sample libraries were generated per manufacturer’s 
specifications on the Hamilton STAR robotics platform. 
The PCR amplified RNA-Seq library products were 
then quantified using the Advanced Analytical Fragment 
Analyzer Standard Sensitivity NGS Fragment Analysis Kit 
(catalog number DNF-473). The samples were diluted to 
10 nanomolar in Qiagen Elution Buffer (Qiagen material 
number 1014609), denatured, and loaded at a range of 2.5 
to 4.0 picomolar on an Illumina cBOT using the HiSeq® 
4000 PE Cluster Kit (catalog number PE-410-1001). The 
RNA-Seq libraries were sequenced on a HiSeq® 4000 at 75 
base pair paired end with 8 base pair dual indexes using the 
HiSeq® 4000 SBS Kit, 150 cycles (catalogue number FC-
410-1002). The sequence intensity files were generated on 
instrument using the Illumina Real Time Analysis software. 
The resulting intensity files were demultiplexed with the 
bcl2fastq2 software and aligned to the human transcriptome 
using Salmon [12] v 0.8.2 and the gencode version 25 basic 
transcriptome. Command line options to salmon quant were 
‘-q–libType IU–seqBias–gcBias –useVBOpt’.
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